Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Barinthus Biotherapeutics plc.
Report date January 03, 2023 · Filed March 29, 2023
Section 16 reporting ended · disclosed 2023-03-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2033-01-03 | Direct | 125,000 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 125,000 · Balance 125,000 F2: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Mar 29, 2023 16:43 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-23-038362 · tm2310913-2_4seq1.xml · derivative · entry 1 Evans Thomas George · CIK 0001851686 · Fmr Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Ordinary Shares · 125,000 shares Expires 2033-01-03 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 03, 2022 Filed Feb 11, 2022 19:54 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $11.12 | $0.00 |
DisclosureSEC source: 0001104659-22-020823 · tm226469-4_4seq1.xml · derivative · entry 1 Evans Thomas George · CIK 0001851686 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Ordinary Shares · 80,000 shares Expires 2032-01-03 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:23 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 364,620 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061219 · tm2114558-16_4seq1.xml · derivative · entry 2 Evans Thomas George · CIK 0001851686 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,620 Underlying: Ordinary Shares · 364,620 shares Expires 2031-04-29 F3 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| April 29, 2021 Filed May 4, 2021 20:23 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 6,942 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001104659-21-061219 · tm2114558-16_4seq1.xml · derivative · entry 1 Evans Thomas George · CIK 0001851686 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,942 Underlying: Ordinary Shares · 6,942 shares Expires 2031-04-29 F1 · derivative.exercise_date: This option shall vest and become exercisable on April 29, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.